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ExtEndEd rEport
Cross-phenotype association mapping of the MHC 
identifies genetic variants that differentiate psoriatic 
arthritis from psoriasis
John Bowes,1 James Ashcroft,1 nick dand,2 Farideh Jalali-najafabadi,1 Eftychia Bellou,1 
pauline Ho,1,3 Helena Marzo-ortega,4 philip S Helliwell,4 Marie Feletar,5 
Anthony W ryan,6 david J Kane,7 Eleanor Korendowych,8 Michael A Simpson,9 
Jonathan packham,10 ross McManus,6 Matthew A Brown,11 Catherine H Smith,12 
Jonathan n Barker,13 neil McHugh,8 oliver FitzGerald,9 richard B Warren,14 
Anne Barton1,3
ABstrAct
Objectives psoriatic arthritis (psA) is a chronic 
inflammatory arthritis, with a strong heritable 
component, affecting patients with psoriasis. Here we 
attempt to identify genetic variants within the major 
histocompatibility complex (MHC) that differentiate 
patients with psA from patients with cutaneous psoriasis 
alone (psC).
Methods 2808 patients with psC, 1945 patients with 
psA and 8920 population controls were genotyped. We 
imputed Snps, amino acids and classical HLA alleles 
across the MHC and tested for association with psA 
compared to population controls and the psC patient 
group. In addition we investigated the impact of the age 
of disease onset on associations.
results HLA-C*06:02 was protective of psA compared 
to psC (p=9.57×10−66, or 0.37). the HLA-C*06:02 risk 
allele was associated with a younger age of psoriasis 
onset in all patients (p=1.01×10−59). After controlling 
for the age of psoriasis onset no association of psA 
to HLA-C*06:02 (p=0.07) was observed; instead, 
the most significant association was to amino acid 
at position 97 of HLA-B (p=1.54×10−9) where the 
presence of asparagine or serine residue increased psA 
risk. Asparagine at position 97 of HLA-B defines the 
HLA-B*27 alleles.
conclusions By controlling for the age of psoriasis 
onset, we show, for the first time, that HLA-C*06:02 is 
not associated with psA and that amino acid position 97 
of HLA-B differentiates psA from psC. this amino acid 
also represents the largest genetic effect for ankylosing 
spondylitis, thereby refining the genetic overlap of 
these two spondyloarthropathies. Correcting for bias 
has important implications for cross-phenotype genetic 
studies.
BAckgrOund
Psoriatic arthritis (PsA) is a chronic inflammatory 
arthropathy characterised by spondylitis, enthesitis 
and arthritis. It is associated with the presence of 
psoriasis, with a prevalence of up to 14% in this 
patient group.1 The presence of PsA has a substan-
tial impact on a patient’s quality of life, which has 
been shown to be lower than that of patients with 
psoriasis alone, partly attributable to increased rates 
of comorbidities such as cardiovascular disease.2 3 
The identification of patients with psoriasis at high 
risk of developing PsA has the potential for signifi-
cant benefit in patient health as it would allow early 
intervention to reduce disability and result in an 
improved outcome for the patient.4
Both psoriasis and PsA have a substantial genetic 
component that influences an individual’s suscep-
tibility; indeed there are now 63  confirmed risk 
loci for psoriasis in populations of European orign.5 
The identification of risk loci that are specific for 
the development of PsA in patients with psoriasis 
has been more challenging, but evidence is now 
emerging of loci associated at genome-wide signif-
icance thresholds with PsA and not PsC, including 
loci at 5q31, IL23R, PTPN22, TNFAIP3 and HLA-
B.6–9 Genes within the major histocompatibility 
complex (MHC), in particular HLA class I genes, 
have been consistently shown to contribute to the 
susceptibility of both PsC and PsA, with indepen-
dent associations to HLA-C, HLA-B and HLA-
A.6 9 10 Of these, the largest effect is observed with 
the HLA-C*06:02 allele, where carriage is associ-
ated with increased risk and lower age of disease 
onset of psoriasis.11 Interestingly a paradoxical 
association of HLA-C*06:02 has been reported 
whereby it is a risk factor for PsA compared with 
controls, but conversely carriage is protective of 
PsA within psoriasis.12–14 Finally, previous studies 
have consistently identified the HLA-B*27 and 
HLA-B*39 alleles as associated with PsA but not 
PsC, while a more recent analysis of the HLA region 
based on amino acids rather than genetic haplo-
types has reported that an amino acid at position 
45 of the mature HLA-B protein is associated with 
PsA in psoriasis.9
The MHC is a particularly challenging region of 
the genome to map due to the presence of multiple 
independent associations and extensive linkage 
disequilibrium between genetic variants. Given the 
complexity of fine-mapping genetic associations in 
the MHC, in this study, we attempt to independently 
validate the previously reported association to 
the amino acid at position 45 of HLA-B. Here we 
fine-map genetic associations that differentiate PsA 
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from PsC in large sample collections using imputed single nucle-
otide polymorphisms (SNPs), classical HLA alleles and amino 
acid residues.
MethOds
PsA cohort
A total of 2217 patients with PsA were recruited from rheuma-
tology centres in the UK, Ireland and Australia, as previously 
described.6 PsA classification was defined as the presence of 
both psoriasis and inflammatory arthritis, regardless of rheuma-
toid factor status, and all had peripheral arthritis. The majority 
of patients satisfied the CASPAR (ClASsification criteria for 
Psoriatic ARthritis) classification system,15 although some were 
collected prior to the introduction of this classification system 
and all patients were diagnosed by a rheumatologist. All patients 
provided written informed consent (UK PsA National Reposi-
tory MREC 99/8/84).
Psoriasis cohort
We had access to data on 1306 psoriasis patient samples obtained 
through the Biomarkers of Systemic Treatment Outcomes in 
Psoriasis study (BSTOP). Patients with severe psoriasis who 
had also consented to the British Association of Dermatolo-
gists Biologics Interventions Registry (a UK pharmacovigilance 
registry,  BADBIR. org. uk) were recruited to BSTOP between 
October 2011 and October 2015 from 60 secondary and 
tertiary care outpatient dermatology departments throughout 
the UK, including centres in London, Manchester, Nottingham 
and Liverpool. All patients provided written informed consent 
(BSTOP ethics reference 11/H0802/7). In addition we had 
access to data on 2622 patients with psoriasis from the Well-
come Trust Case Control Consortium 2 (WTCCC2) study.16 
Samples from each of these collections were only included 
in the analysis if they had no previous diagnosis of PsA; we 
refer to this sample group as cutaneous-only psoriasis (PsC). 
Classification of PsC in the BSTOP cohort is based on infor-
mation collected at multiple follow-up consultancies, one 
every 6 months in the first 3 years and then annually, where an 
active enquiry of rheumatologist-diagnosed PsA is made. Indi-
viduals from the WTCCC2 cohort were excluded based on a 
known diagnosis of PsA using information provided by sample 
contributors.
Population control cohort
A total of 9006 population controls were obtained through the 
1958 British birth cohort and the UK Blood Service control 
group. In addition control data were available from 478 individ-
uals from Ireland.
genotyping and quality control
PsA and control population samples were genotyped using the 
Illumina Immunochip array as previously described, and details 
are provided in the online supplementary text.6 Psoriasis samples 
were genotyped using the Illumina HumanOmniExpressEx-
ome-8v1-2_A array performed at King’s College London. 
Automated genotype reclustering was performed followed by 
extensive manual review of genotype clusters based on GenTrain 
score, cluster separation, allele frequency and call rate. Data 
for the additional psoriasis samples from the WTCCC2 psori-
asis GWAS were generated using the Illumina Human660-Quad 
genotyping array as previously described.16
statistical quality control
Statistical quality control (QC) was performed conforming 
to established standards in each data set independently. The 
Immunochip data set (PsA and control samples) was filtered 
as previously described and details are provided in the online 
supplementary text.6 Statistical QC of the BSTOP data set 
consisted of the exclusion of samples with a call rate <0.99 and 
with discrepant sex based on inferred and labelled sex, exclusion 
of duplicate and related samples using identity-by-state analysis 
on a set of 75 784 linkage disequilibrium (LD)-pruned SNPs 
with minor allele freqeuncy (MAF) >0.1 in KING (V.1.4), and 
exclusion of outliers based on ancestry via principal compo-
nent analysis (PCA) on the LD-pruned SNPs (also using KING). 
SNPs were excluded with a call rate <0.99 or Hardy-Weinberg 
deviation of p<7.5×10−8. Both data sets were aligned to the 
forward strand of the haplotype reference consortium (HRC) 
reference panel (HRC.r1-1.GRCh37) using the HRC checking 
tool (http://www. well. ox. ac. uk/~ wrayner/ tools/). QC of the 
WTCCC2 data set has been described previously16; in addi-
tion to this we excluded known PsA samples from the data set, 
leaving a total of 1784 PsC samples. The data sets were merged 
and intersecting SNPs were retained. Identity by descent (IBD) 
was performed on the combined genotype data to identify any 
overlapping samples.
Imputation of Mhc markers
Imputation of HLA alleles, amino acids and SNPs within the HLA 
region (chr6:29–34, hg19) was performed with the SNP2HLA 
software package (V.1.0.3) using the T1DGC reference panel.17 
Analysis was performed using the imputed dosage on all variants 
with an information score ≥0.9 and an MAF ≥0.1.
statistical analysis
Analysis of all markers was performed using logistic regression 
assuming an additive effect based on the carriage of alleles. 
Population structure was controlled for by including the top 
two principal components as covariates calculated using an 
intersection of non-HLA SNPs in the combined data set (online 
supplementary figure S1). For multiallelic sites, such as amino 
acids, we identified the most common residue or allele in the 
control population to be selected as the reference and excluded 
from the model. The p value for each marker was derived from 
an omnibus test performed with a log-likelihood ratio test of 
the null and fitted models. Forward stepwise logistic regression 
was used to identify independent effects where the top marker, 
ranked by the log-likelihood p value, was included as a covariate 
by addition to the null model. This was repeated until no further 
marker reached a predefined significance threshold based on the 
Bonferroni-corrected type I error rate for the number of markers 
in the data set. Interactions between the HLA-B*27 allele and 
non-HLA SNPs were tested in the PsA and control Immuno-
chip data set by fitting an interaction term in the logistic model 
with HLA-B*27 fitted as a dominant term and the SNP as an 
additive term.18 We tested interactions with rs30187 (ERAP1), 
a previously reported interaction in ankylosing spondylitis (AS), 
and also to rs12044149 (IL23R), rs715285 (5q31), rs2476601 
(PTPN22) and rs9321623 (TNFAIP3), which have previously 
been reported as differentiating PsA from PsC.6 8 18 19 Associa-
tion of genetic markers with age of psoriasis onset, as a contin-
uous variable, was tested using linear regression, and a difference 
in the median age of onset between groups was tested using a 
Wilcoxon test.
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results
After QC the study data set comprised 1945 PsA cases, 2808 
PsC cases and 8920 control samples for 6833 SNPs, 334 amino 
acids, 71 classical HLA alleles at two-digit resolution and 87 
classical HLA alleles at four-digit resolution. A Bonferroni-cor-
rected threshold for p values of 6.8×10–6 based on a total of 
7325 markers was used to determine significant associations.
the paradoxical association of hlA-c*06:02 and PsA
First, we compared the imputed dosages for all MHC markers 
for each of the disease groups, PsC and PsA, with the popula-
tion control group. As expected we replicated the three previ-
ously reported independent associations to the class I genes 
HLA-C (HLA-C*06:02), HLA-B (amino acid position 67) and 
HLA-A (HLA-A*02:01 or the highly correlated amino acid at 
position 95, r2 valine=0.99) for each of the diseases (online 
supplementary figures S2 and S3). We then directly compared 
PsA with PsC (PsC labelled as the reference group) and observed 
the most significant association was to the HLA-C*06:02 allele 
(p=9.57×10−66), where the presence of the allele was protec-
tive of PsA compared with PsC (OR 0.37, 95% CI 0.33 to 0.41) 
(figure 1A); the result was in contrast to the previous compar-
ison against controls where the allele was a risk factor for PsA 
(p=7.44×10−48, OR 2.13, 95% CI 1.92 to 2.35). The associa-
tion remained significant after conditioning on the previously 
reported HLA-B amino acid position 45 (p=6.88×10−27).
hlA-c*06:02 is associated with the age of onset of psoriasis
Given the previously reported association of HLA-C*06:02 
with age of psoriasis onset, we investigated the potential for 
confounding of the statistical analysis due to selection bias in 
a data set of 2050 case-only samples with relevant phenotype 
data (PsA=981, PsC=1069). We found significant association of 
HLA-C*06:02 allele dose with a younger age of psoriasis onset 
in all samples (p=1.01×10−59; online supplementary figure S4a) 
and that carriage of the risk allele resulted in a difference in the 
median age of psoriasis onset of approximately 14 years (online 
supplementary figure S4b). We found a significant difference 
(p=1.85×10−71) in the median age of psoriasis onset between 
the PsC (19 years, IQR 15 years) and the PsA groups (34 years, 
IQR 27 years) (online supplementary figure S5). This result 
illustrates the potential for confounding when investigating 
features known to be associated with age of onset as is the case 
for HLA-C*06:02.
Psoriasis age of onset confounds hlA analyses
All association analyses comparing PsA with PsC were repeated 
while conditioning on age of psoriasis onset as a covariate 
(figure 1B). Within this subgroup of samples, HLA-C*06:02 
is significantly associated with a protective effect on PsA 
(p=4.17×10−15, OR 0.52, 95% CI 0.44 to 0.61); however, when 
conditioning on age of psoriasis onset, there was no evidence 
of association between HLA-C*06:02 and PsA (p=0.07), 
suggesting the previously observed protective effect was the 
result of confounding due to the different age of psoriasis onset 
in the disease subgroup strata.
Amino acid position 97 of hlA-B differentiates PsA from Psc
The most significant association with PsA compared with PsC 
after correcting for age of psoriasis onset was to an amino acid at 
position 97 of HLA-B (p=1.54×10−9), where the presence of an 
asparagine (OR 2.46, 95% CI 1.78 to 3.42) or serine (OR 1.45, 
95% CI 1.22 to 1.74) residue increased the risk of PsA (table 1). 
An asparagine residue at position 97 of HLA-B is predominantly 
found on HLA-B*27 alleles, and HLA-B*27:05 is the most 
associated HLA allele after correcting for age of psoriasis onset 
(p=3.53×10−7, OR 2.34, 95% CI 1.69 to 3.25); in addition, a 
serine residue is found on multiple HLA alleles including HLA-
B*07 (p=1.9×10−3) and HLA-B*08 (p=0.05). However neither 
of these two alleles were independently associated with PsA when 
conditioning on amino acid position 97 (p>0.05), while amino 
acid 97 remained associated independently of either of these two 
HLA alleles and was independently associated when adjusting for 
HLA-B*27, indicating that amino acid 97 is the primary driver of 
the associations observed with these HLA-B alleles. This amino 
acid is an important risk factor for AS; comparison of effect esti-
mates shows that an asparagine residue increases risk for both 
diseases, although with a substantially larger effect estimate in 
AS (OR 16.51, 95% CI 15.43 to 17.69) than PsA (OR 2.46, 
95% CI 1.78 to 3.42) (figure 2).20 In contrast, the presence of a 
serine residue is associated with risk of PsA (OR 1.45, 95% CI 
1.22 to 1.74) while reported to have a protective effect for AS 
(OR 0.86, 95% CI 0.81 to 0.91).
p Value and ORs are determined with multivariate logistic 
regression.
We found significant association to the previously reported 
amino acid at position 45 of HLA-B (p=3.5×10−4; online 
supplementary table S1); however, this was not significant after 
adjusting for amino acid position 97 (p=0.16). No further 
associations exceeded the significance threshold when condi-
tioning on amino acid 97 (figure 1C). We found no evidence to 
support the previously reported interaction between HLA-B*27 
and ERAP1 observed in AS or with any of the other previously 
reported PsA differentiating loci (p value >0.05).
dIscussIOn
Through detailed analysis of the MHC region using data from 
patients with PsA, PsC and population controls, we show that, 
first, previous reports of a protective effect of HLA-C*06:02 
with PsA are due to confounding by differences in the age of 
onset of psoriasis due to the strong association of HLA-C*06:02 
with a younger age of psoriasis onset; second, HLA-C*06:02 and 
HLA-A*02:01 are primarily associated with psoriasis and confer 
no additional risk of PsA; and, third, that when age of psoriasis 
onset is accounted for, the primary association conferring addi-
tional risk for PsA in patients with psoriasis is to the presence 
of asparagine (HLA-B*27) or serine (HLA-B*07 and HLA-B*08) 
residues at amino acid position 97 of HLA-B.
Understanding the genetic factors that differentiate PsA from 
PsC is important both for screening patients at risk for psori-
asis and for understanding the disease mechanisms involved. 
In terms of screening, given that psoriasis often predates PsA, 
factors that identify a group of patients with psoriasis at higher 
risk of developing PsA could potentially allow the introduction 
of preventative strategies in the future. Indeed, the application 
of genetic risk scores in high-risk groups where disease prev-
alence is much higher than the general population has been 
shown to greatly increase the diagnostic benefit of genetic risk 
factors.21 At a practical level, however, while genotyping costs 
have improved, analysis and interpretation of HLA data from 
genotyping arrays remain time-consuming and challenging, and 
it is still not clear how much more information is provided over 
and above classical HLA typing methods. Thus, if HLA screening 
were shown to be useful in prospective studies of patients with 
psoriasis, HLA typing for HLA-B*27 may remain the preferred 
option.
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Okada et al report residues at the amino acid position 45 
of HLA-B as the key risk factor for PsA in psoriasis; however, 
the current study does not support this after correcting for 
the age of psoriasis onset (p value=3.5×10−4). PsA is a clin-
ically heterogeneous disease and one possible explanation of 
this discrepancy is differing proportions of clinical subgroups 
between the studies. For example HLA-B*27 has been reported 
to be associated with axial disease within a well-phenotyped PsA 
patient cohort22; therefore, the current study may be enriched 
for axial disease. This highlights the need for accurate clinical 
phenotyping of PsA cases, and one of the major limitations of the 
current study was that this could not be investigated further due 
to the lack of information about the presence of axial disease in 
all of our patients with PsA.
Amino acid position 97 of HLA-B represents the largest genetic 
effect reported in AS20; our analysis has confirmed the genetic 
overlap of PsA with AS. It could be argued that PsA may simply 
be an overlap of AS and psoriasis, but clinical, radiographic and 
genetic differences have been observed. For example, metho-
trexate is more effective in PsA than AS; classical pencil-in-cup 
Figure 1 Association results for (A) PsA compared with PsC, (B) PsA compared with PsC controlling for age of psoriasis onset and (C) PsA compared 
with PsC controlling for age of psoriasis onset and association at amino acid position 97 at HLA-B. Red horizontal line indicates significance threshold; 
y-axis is –log10 of the omnibus test p value, and the x-axis indicates chromosomal base position and gene locations. PsA, psoriatic arthritis. 
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deformities, osteolysis and juxta-articular new bone formation 
in hands and feet are more common in PsA, and genetic variants 
have been identified that are associated with one disease but not 
the other; for example, PsA variants at the IL23R are distinct 
from those reported for AS.6 Amino acid residues at position 
97 are the most important risk factor for both diseases, and our 
results highlight both overlapping and differential associations. 
The asparagine residue is associated with increased risk in both 
diseases; however, the serine residue has a differential associa-
tion representing increased risk for PsA while being protective 
of AS. The position is located within the peptide binding groove 
of the HLA-B molecule and highlights the importance of antigen 
presentation in disease aetiology. We were unable to replicate the 
interaction of HLA-B*27 and ERAP1 observed in AS.18 This may 
be due to insufficient power of the current study to detect an 
interaction due to the lower effect sizes in PsA or could indicate 
differing disease mechanisms.
Our study highlights the importance of accounting for 
confounding in genetic studies, particularly when associated 
loci are correlated with timing of disease onset. We believe the 
confounding observed in this study is due to ascertainment bias 
where cases of type I psoriasis, age of onset <40 years, are pref-
erentially included in genetic studies and such selection does not 
occur in PsA collections. The issue of selection bias is increasingly 
being recognised in the statistical methodology literature.23 24 In 
particular, index event bias describes how conditioning on an 
outcome, for example psoriasis, can induce correlation between 
risk factors leading to spurious associations.
In conclusion, we show that HLA-C*06:02 is primarily asso-
ciated with psoriasis with no effect, either risk or protective, 
on PsA, while HLA-B amino acid 97, the same variant that 
represents the major AS risk factor, is the most important risk 
factor for PsA.
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